retatrutide trial results Retatrutide, an Amazing Future for Weight Loss

New Phase 3 retatrutide data just dropped 👀 Eli Lilly's trial reported average weight loss approaching 30%, with some patients achieving results historically associated with bariatric surgery. A few important caveats: •

25.02

★★★★☆4.8 (126)

Today we shared new results on retatrutide, an investigational, first-of-its-kind treatment we're studying in adults with obesity or overweight with at least one weight-related comorbidity. Read more about the Phase 3 findings:

22.48

★★★★★4.9 (98)

Eli Lilly infiltrates anti-obesity market as Phase III trial for retatrutide begins

23.27

★★★★★5.0 (157)

Retatrutide Results: How Much Weight Can You Lose & How Quick?

27.48

★★★★★4.7 (84)

NEW Data drop at #ADA2023: Retatrutide, a triple agonist (GLP1, GIP, glucagon) lost an incredible 24.2% of their body weight, which amounts to 58 lbs! This data suggests retatrutide is the most

24.52

★★★★★4.9 (203)

Retatrutide just delivered the first top-line Phase 3 results for a triple agonist in obesity — and the findings from TRIUMPH-4 are striking👇

27.32

★★★★★5.0 (176)

Retatrutide, a new weight loss drug not available on the market yet, is showing promising results in trials. @DrLaPook explains it's doing much more than what current medications can

22.27

★★★★★4.8 (132)